ProMIS Neurosciences Inc. (PMN) - Total Assets
Based on the latest financial reports, ProMIS Neurosciences Inc. (PMN) holds total assets worth $21.46 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ProMIS Neurosciences Inc. - Total Assets Trend (2005–2024)
This chart illustrates how ProMIS Neurosciences Inc.'s total assets have evolved over time, based on quarterly financial data. Also see market value of ProMIS Neurosciences Inc. for the company's overall valuation and market capitalisation.
ProMIS Neurosciences Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
ProMIS Neurosciences Inc.'s total assets of $21.46 Million consist of 100.0% current assets and 0.0% non-current assets. Review PMN total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 70.3% |
| Accounts Receivable | $78.03K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how ProMIS Neurosciences Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See PMN stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ProMIS Neurosciences Inc.'s current assets represent 100.0% of total assets in 2024, an increase from 98.5% in 2005.
- Cash Position: Cash and equivalents constituted 70.3% of total assets in 2024, up from 2.1% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
ProMIS Neurosciences Inc. Competitors by Total Assets
Key competitors of ProMIS Neurosciences Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
ProMIS Neurosciences Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.76 | 9.30 | 0.20 |
| Quick Ratio | 1.76 | 9.30 | 0.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.25 Million | $21.88 Million | $-2.19 Million |
ProMIS Neurosciences Inc. - Advanced Valuation Insights
This section examines the relationship between ProMIS Neurosciences Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.86 |
| Latest Market Cap to Assets Ratio | 1.53 |
| Asset Growth Rate (YoY) | 38.9% |
| Total Assets | $18.91 Million |
| Market Capitalization | $28.97 Million USD |
Valuation Analysis
Above Book Valuation: The market values ProMIS Neurosciences Inc.'s assets above their book value (1.53x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: ProMIS Neurosciences Inc.'s assets grew by 38.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ProMIS Neurosciences Inc. (2005–2024)
The table below shows the annual total assets of ProMIS Neurosciences Inc. from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $18.91 Million | +38.86% |
| 2023-12-31 | $13.62 Million | +45.26% |
| 2022-12-31 | $9.38 Million | -58.22% |
| 2021-12-31 | $22.44 Million | +1520.47% |
| 2020-12-31 | $1.38 Million | -33.22% |
| 2019-12-31 | $2.07 Million | -30.09% |
| 2018-12-31 | $2.97 Million | +36.63% |
| 2017-12-31 | $2.17 Million | +124.30% |
| 2016-12-31 | $967.82K | -15.90% |
| 2015-12-31 | $1.15 Million | +290.69% |
| 2013-12-31 | $294.54K | -6.88% |
| 2012-12-31 | $316.29K | -1.72% |
| 2011-12-31 | $321.81K | +24770.78% |
| 2010-12-31 | $1.29K | -99.98% |
| 2009-12-31 | $5.31 Million | +21.43% |
| 2008-12-31 | $4.37 Million | -54.98% |
| 2007-12-31 | $9.71 Million | -24.01% |
| 2006-12-31 | $12.77 Million | +168.42% |
| 2005-12-31 | $4.76 Million | -- |
About ProMIS Neurosciences Inc.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product c… Read more